{"title":"Novel mutation <i>SLFN14</i> T853fs associated with inherited macrothrombocytopenia.","authors":"Haixiao Xie, Shiyi Tang, Jianmin Shao, Ming Yang, Huida Tong, Linhua Zhang, Mingzhu Zhong, Xiaomin Yu, Laixi Bi, Yuming Wang, Rongying Ou, Chen Ling, Liqing Zhu","doi":"10.1016/j.omtn.2025.102554","DOIUrl":null,"url":null,"abstract":"<p><p><i>SLFN14</i>-related inherited thrombocytopenia (<i>SLFN14</i>-related IT) is a hereditary disorder involving ribosomopathy and platelet dysfunction. Affected patients exhibit significant bleeding tendencies. To date, five affected pedigrees have been reported, all harboring mutations within the \"ATPase associated with diverse cellular activities\" (AAA) domain. In this study, we identified a novel T853fs variant located in the \"helicase\" domain. SLFN14 expression was markedly reduced in platelets from the patients and in Meg-01 cells transfected with T853fs plasmid. Functional assays revealed a defection of T853fs variant in both arachidonic acid (AA)-induced aggregation and fibrinogen-induced adhesion. Unlike previously reported mutations in the AAA domain, which significantly upregulate ribosomal protein genes and mitochondrial translation pathways, the T853fs mutation identified in this study did not affect mitochondrial translation. Immunofluorescence assay showed that T853fs variant exhibited diffuse cytoplasmic localization. Further RNA sequencing (RNA-seq) analysis revealed the significant regulation of T853fs mutation on pathways related to ion channels and dense granule, which are crucial to platelet function. In conclusion, this study identifies a new <i>SLFN14</i> mutation and highlights the phenotypic diversity of SLFN14-RT.</p>","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":"36 2","pages":"102554"},"PeriodicalIF":6.1000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159219/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2025.102554","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/10 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
SLFN14-related inherited thrombocytopenia (SLFN14-related IT) is a hereditary disorder involving ribosomopathy and platelet dysfunction. Affected patients exhibit significant bleeding tendencies. To date, five affected pedigrees have been reported, all harboring mutations within the "ATPase associated with diverse cellular activities" (AAA) domain. In this study, we identified a novel T853fs variant located in the "helicase" domain. SLFN14 expression was markedly reduced in platelets from the patients and in Meg-01 cells transfected with T853fs plasmid. Functional assays revealed a defection of T853fs variant in both arachidonic acid (AA)-induced aggregation and fibrinogen-induced adhesion. Unlike previously reported mutations in the AAA domain, which significantly upregulate ribosomal protein genes and mitochondrial translation pathways, the T853fs mutation identified in this study did not affect mitochondrial translation. Immunofluorescence assay showed that T853fs variant exhibited diffuse cytoplasmic localization. Further RNA sequencing (RNA-seq) analysis revealed the significant regulation of T853fs mutation on pathways related to ion channels and dense granule, which are crucial to platelet function. In conclusion, this study identifies a new SLFN14 mutation and highlights the phenotypic diversity of SLFN14-RT.
期刊介绍:
Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.